|
|
|
|
| LEADER |
02792nmm a2200361 u 4500 |
| 001 |
EB000674334 |
| 003 |
EBX01000000000000000527416 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642784262
|
| 100 |
1 |
|
|a Schettler, Gotthard
|e [editor]
|
| 245 |
0 |
0 |
|a Principles and Treatment of Lipoprotein Disorders
|h Elektronische Ressource
|c edited by Gotthard Schettler, Andreas J.R. Habenicht
|
| 250 |
|
|
|a 1st ed. 1994
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 1994, 1994
|
| 300 |
|
|
|a XXIII, 502 p
|b online resource
|
| 505 |
0 |
|
|a Section A: Physiology and Pathophysiology of Lipid Metabolism -- 1 An Introduction to the Biochemistry and Biology of Blood Lipids and Lipoproteins -- 2 Lipoprotein Metabolism -- 3 Lipoprotein Receptors -- 4 Genetic Disorders of Lipoprotein Metabolism -- 5 Interactions Between Lipoproteins and the Arterial Wall -- 6 Lipoprotein Lipase and Hepatic Lipase -- 7 Animal Models of Lipoprotein Metabolism -- Section B: Lipid Lowering Therapy -- 8 Rationale to Treat -- 9 The Dietary Therapy of Hyperlipidemia: Its Important Role in the Prevention of Coronary Heart Disease -- 10 Lipid Apheresis -- Section C: Lipid Lowering Drugs -- 11 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors -- 12 Fibrates -- 13 Nicotinic Acid and Derivatives -- 14 Ion Exchange Resins -- 15 Probucol -- 16 Miscellaneous Lipid-Lowering Drugs
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Cardiology
|
| 653 |
|
|
|a Human Physiology
|
| 653 |
|
|
|a Human physiology
|
| 653 |
|
|
|a Internal Medicine
|
| 653 |
|
|
|a Biochemistry
|
| 653 |
|
|
|a Gastroenterology
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Habenicht, Andreas J.R.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-78426-2
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-78426-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|
| 520 |
|
|
|a Major advances have been made in the understanding of the molecular mechanisms of atherosclerosis, the disease that still affects more than 50 percent of the population in the highly industrialized countries. This volume covers the most recent advances in the treatment of hyperlipidemia. It represents a necessary update because molecular mechanisms of atherogenesis have been discovered in the past few years and their molecular mechanisms of action identified. Extensively treated are the molecular mechanisms of disease etiology of arteriosclerosis in relation to the major risk factor "hyperlipidemia", rationale for more effective treatment of this disease by dietary means, the treatment of associated or causing diseases, and the treatment using hypolipidemic drugs
|